ALLO
HealthcareAllogene Therapeutics, Inc.
$2.38-0.09 (-3.64%)
Prev Close
$2.47
Open
$2.56
High
$2.73
Low
$2.36
Volume
4.20M
Market Cap
$562.9M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Allogene Therapeutics, Inc. (ALLO) has been exclusively selling, with 0 insider purchases totaling $0.00 and 21 insider sales totaling $1.01M. The most recent insider transaction was by Beneski Benjamin Machinas (officer: SVP, Chief Technical Officer), who sold $37.1K worth of shares on Mar 4, 2026. Allogene Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $562.9M.
Buys (12M)
0
$0.00
Sells (12M)
21
$1.01M
Net Activity
Net Seller
$1.01M
Active Insiders
7
last 12 mo
ALLO Price Chart
ALLO Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026↗ | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 14,264 | $2.60 | $37.1K | 203,040 |
| Feb 4, 2026↗ | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 7,549 | $1.73 | $13.1K | 210,172 |
| Feb 4, 2026↗ | Chang David D | director, officer: President and CEO | Sell | 95,269 | $1.80 | $171.5K | 5,185,860 |
| Feb 4, 2026↗ | Douglas Earl Martin | officer: SVP, General Counsel | Sell | 22,900 | $1.76 | $40.3K | 564,948 |
| Feb 4, 2026↗ | Parker Geoffrey M. | officer: CHIEF FINANCIAL OFFICER | Sell | 24,001 | $1.76 | $42.2K | 1,252,800 |
| Feb 4, 2026↗ | Roberts Zachary | officer: EVP of R&D | Sell | 35,700 | $1.77 | $63.2K | 581,166 |
| Feb 4, 2026↗ | Yoshiyama Annie | officer: SVP, Finance | Sell | 4,167 | $1.72 | $7.2K | 130,322 |
| Feb 2, 2026↗ | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 7,549 | $1.73 | $13.1K | 0 |
| Feb 2, 2026↗ | Chang David D | President and CEO | Sell | 95,269 | $1.80 | $171.5K | 0 |
| Feb 2, 2026↗ | Douglas Earl Martin | SVP, General Counsel | Sell | 22,900 | $1.76 | $40.3K | 0 |
| Feb 2, 2026↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 24,001 | $1.76 | $42.2K | 0 |
| Feb 2, 2026↗ | Roberts Zachary | EVP of R&D | Sell | 35,700 | $1.77 | $63.2K | 0 |
| Feb 2, 2026↗ | Yoshiyama Annie | SVP, Finance | Sell | 4,167 | $1.72 | $7.2K | 0 |
| Jan 23, 2026↗ | Roberts Zachary | officer: EVP of R&D | Sell | 26,269 | $1.56 | $41.0K | 616,866 |
| Jan 21, 2026↗ | Roberts Zachary | EVP of R&D | Sell | 26,269 | $1.56 | $41.0K | 0 |
| Nov 17, 2025↗ | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 786 | $1.22 | $958.92 | 0 |
| Oct 21, 2025↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,744 | $1.26 | $46.2K | 0 |
| Jun 10, 2025↗ | MESSEMER DEBORAH M. | Director | Sell | 36,885 | $1.42 | $52.4K | 0 |
| Apr 21, 2025↗ | Yoshiyama Annie | SVP, Finance | Sell | 9,601 | $1.41 | $13.5K | 0 |
| Mar 14, 2025↗ | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 5,488 | $1.98 | $10.8K | 0 |
| Mar 14, 2025↗ | Chang David D | President and CEO | Sell | 46,668 | $1.96 | $91.5K | 0 |
| Feb 18, 2025↗ | MESSEMER DEBORAH M. | Director | Sell | 13,313 | $2.43 | $32.4K | 0 |
| Feb 3, 2025↗ | Chang David D | President and CEO | Sell | 46,003 | $1.68 | $77.3K | 0 |
| Feb 3, 2025↗ | Douglas Earl Martin | SVP, General Counsel | Sell | 6,404 | $1.71 | $11.0K | 0 |
| Feb 3, 2025↗ | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 14,746 | $1.71 | $25.2K | 0 |
| Feb 3, 2025↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 4,361 | $1.73 | $7.5K | 0 |
| Feb 3, 2025↗ | Roberts Zachary | EVP of R&D | Sell | 18,832 | $1.70 | $32.0K | 0 |
| Jan 21, 2025↗ | Roberts Zachary | EVP of R&D | Sell | 27,199 | $1.78 | $48.4K | 0 |
| Dec 9, 2024↗ | MESSEMER DEBORAH M. | Director | Sell | 9,136 | $2.18 | $19.9K | 0 |
| Dec 5, 2024↗ | Humer Franz B | Director | Sell | 9,221 | $2.16 | $19.9K | 0 |
| Oct 21, 2024↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,404 | $2.84 | $103.4K | 0 |
| Aug 21, 2024↗ | Douglas Earl Martin | SVP, General Counsel | Sell | 28,310 | $2.79 | $78.8K | 0 |
| Jun 18, 2024↗ | MESSEMER DEBORAH M. | Director | Sell | 18,641 | $2.28 | $42.5K | 0 |
| May 30, 2024↗ | Humer Franz B | Director | Sell | 11,200 | $2.34 | $26.2K | 0 |
| May 16, 2024↗ | Belldegrun Arie | Director | Buy | 1,724,137 | $2.90 | $5.00M | 0 |
| Apr 22, 2024↗ | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 17,360 | $3.47 | $60.2K | 0 |
| Mar 14, 2024↗ | Chang David D | President and CEO | Sell | 53,393 | $4.33 | $231.2K | 0 |
| Jan 30, 2024↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Buy | 190 | $3.60 | $683.05 | 0 |
| Jan 22, 2024↗ | Roberts Zachary | EVP of R&D | Sell | 24,690 | $3.17 | $78.4K | 0 |
| Dec 18, 2023↗ | MESSEMER DEBORAH M. | Director | Sell | 18,640 | $2.70 | $50.3K | 0 |
| Aug 7, 2023↗ | Mayo Stephen | Director | Sell | 10,000 | $4.29 | $42.9K | 0 |
| Mar 14, 2023↗ | Bhavnagri Veer | General Counsel | Sell | 23,628 | $5.67 | $134.0K | 0 |
| Mar 14, 2023↗ | Chang David D | President and CEO | Sell | 22,340 | $5.56 | $124.2K | 0 |
| Mar 14, 2023↗ | MOORE ALISON | Chief Technical Officer | Sell | 8,351 | $5.51 | $46.0K | 0 |
| Mar 14, 2023↗ | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 35,879 | $5.47 | $196.3K | 0 |
| Feb 13, 2023↗ | Bhavnagri Veer | General Counsel | Sell | 3,000 | $6.85 | $20.6K | 0 |
| Jan 17, 2023↗ | Bhavnagri Veer | General Counsel | Sell | 3,000 | $7.04 | $21.1K | 0 |
| Dec 15, 2022↗ | Bhavnagri Veer | General Counsel | Sell | 5,602 | $7.53 | $42.2K | 0 |
| Oct 7, 2022↗ | Amado Rafael | EVP of R&D | Sell | 8,464 | $11.83 | $100.1K | 0 |
| Oct 3, 2022↗ | Amado Rafael | EVP of R&D | Sell | 8,968 | $11.06 | $99.2K | 0 |
| Aug 11, 2022↗ | WITTE OWEN N. | Director | Sell | 30,000 | $16.75 | $502.5K | 0 |
| Aug 2, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.97 | $23.9K | 0 |
| Jul 5, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.44 | $22.9K | 0 |
| Jun 22, 2022↗ | WITTE OWEN N. | Director | Sell | 10,000 | $11.76 | $117.6K | 0 |
| Jun 21, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.18 | $22.4K | 0 |
| May 19, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 11,500 | $7.40 | $85.1K | 0 |
| Mar 15, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 5,169 | $7.71 | $39.8K | 0 |
| Mar 15, 2022↗ | Bhavnagri Veer | General Counsel | Sell | 8,849 | $7.68 | $68.0K | 0 |
| Mar 15, 2022↗ | Chang David D | President and CEO | Sell | 23,648 | $7.65 | $180.9K | 0 |
| Mar 15, 2022↗ | MOORE ALISON | Chief Technical Officer | Sell | 8,698 | $7.63 | $66.4K | 0 |
| Mar 15, 2022↗ | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 11,469 | $7.63 | $87.6K | 0 |
| Jan 12, 2022↗ | Belldegrun Arie | Director | Buy | 155,039 | $12.60 | $1.95M | 0 |
| Jan 12, 2022↗ | Kazam Joshua A | Director | Buy | 15,000 | $12.60 | $189.0K | 0 |
| Oct 1, 2021↗ | Amado Rafael | EVP of R&D and CMO | Sell | 11,507 | $24.35 | $280.2K | 0 |
| Sep 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $24.77 | $123.8K | 0 |
| Sep 9, 2021↗ | WITTE OWEN N. | Director | Sell | 5,000 | $25.54 | $127.7K | 0 |
| Aug 20, 2021↗ | WITTE OWEN N. | Director | Sell | 10,000 | $23.47 | $234.7K | 0 |
| Aug 16, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $21.00 | $105.0K | 0 |
| Jul 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $21.55 | $107.8K | 0 |
| Jun 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $25.32 | $126.6K | 0 |
| Jun 9, 2021↗ | WITTE OWEN N. | Director | Sell | 9,969 | $25.05 | $249.7K | 0 |
| May 18, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $30.00 | $150.0K | 0 |
| May 17, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $28.30 | $141.5K | 0 |
| Apr 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 10,000 | $32.05 | $320.5K | 0 |
| Mar 15, 2021↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,798 | $38.05 | $106.5K | 0 |
| Mar 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 16,623 | $37.95 | $630.8K | 0 |
| Mar 15, 2021↗ | Chang David D | President and CEO | Sell | 20,513 | $38.57 | $791.3K | 0 |
| Mar 15, 2021↗ | MOORE ALISON | Chief Technical Officer | Sell | 6,164 | $38.14 | $235.1K | 0 |
| Mar 15, 2021↗ | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 8,053 | $38.23 | $307.9K | 0 |
ALLO Insider Buying Activity
The following table shows recent insider purchases of Allogene Therapeutics, Inc. (ALLO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 16, 2024↗ | Belldegrun Arie | Director | Buy | 1,724,137 | $2.90 | $5.00M | 0 |
| Jan 30, 2024↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Buy | 190 | $3.60 | $683.05 | 0 |
| Jan 12, 2022↗ | Belldegrun Arie | Director | Buy | 155,039 | $12.60 | $1.95M | 0 |
| Jan 12, 2022↗ | Kazam Joshua A | Director | Buy | 15,000 | $12.60 | $189.0K | 0 |
ALLO Insider Selling Activity
The following table shows recent insider sales of Allogene Therapeutics, Inc. (ALLO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026↗ | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 14,264 | $2.60 | $37.1K | 203,040 |
| Feb 4, 2026↗ | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 7,549 | $1.73 | $13.1K | 210,172 |
| Feb 4, 2026↗ | Chang David D | director, officer: President and CEO | Sell | 95,269 | $1.80 | $171.5K | 5,185,860 |
| Feb 4, 2026↗ | Douglas Earl Martin | officer: SVP, General Counsel | Sell | 22,900 | $1.76 | $40.3K | 564,948 |
| Feb 4, 2026↗ | Parker Geoffrey M. | officer: CHIEF FINANCIAL OFFICER | Sell | 24,001 | $1.76 | $42.2K | 1,252,800 |
| Feb 4, 2026↗ | Roberts Zachary | officer: EVP of R&D | Sell | 35,700 | $1.77 | $63.2K | 581,166 |
| Feb 4, 2026↗ | Yoshiyama Annie | officer: SVP, Finance | Sell | 4,167 | $1.72 | $7.2K | 130,322 |
| Feb 2, 2026↗ | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 7,549 | $1.73 | $13.1K | 0 |
| Feb 2, 2026↗ | Chang David D | President and CEO | Sell | 95,269 | $1.80 | $171.5K | 0 |
| Feb 2, 2026↗ | Douglas Earl Martin | SVP, General Counsel | Sell | 22,900 | $1.76 | $40.3K | 0 |
| Feb 2, 2026↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 24,001 | $1.76 | $42.2K | 0 |
| Feb 2, 2026↗ | Roberts Zachary | EVP of R&D | Sell | 35,700 | $1.77 | $63.2K | 0 |
| Feb 2, 2026↗ | Yoshiyama Annie | SVP, Finance | Sell | 4,167 | $1.72 | $7.2K | 0 |
| Jan 23, 2026↗ | Roberts Zachary | officer: EVP of R&D | Sell | 26,269 | $1.56 | $41.0K | 616,866 |
| Jan 21, 2026↗ | Roberts Zachary | EVP of R&D | Sell | 26,269 | $1.56 | $41.0K | 0 |
| Nov 17, 2025↗ | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 786 | $1.22 | $958.92 | 0 |
| Oct 21, 2025↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,744 | $1.26 | $46.2K | 0 |
| Jun 10, 2025↗ | MESSEMER DEBORAH M. | Director | Sell | 36,885 | $1.42 | $52.4K | 0 |
| Apr 21, 2025↗ | Yoshiyama Annie | SVP, Finance | Sell | 9,601 | $1.41 | $13.5K | 0 |
| Mar 14, 2025↗ | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 5,488 | $1.98 | $10.8K | 0 |
| Mar 14, 2025↗ | Chang David D | President and CEO | Sell | 46,668 | $1.96 | $91.5K | 0 |
| Feb 18, 2025↗ | MESSEMER DEBORAH M. | Director | Sell | 13,313 | $2.43 | $32.4K | 0 |
| Feb 3, 2025↗ | Chang David D | President and CEO | Sell | 46,003 | $1.68 | $77.3K | 0 |
| Feb 3, 2025↗ | Douglas Earl Martin | SVP, General Counsel | Sell | 6,404 | $1.71 | $11.0K | 0 |
| Feb 3, 2025↗ | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 14,746 | $1.71 | $25.2K | 0 |
| Feb 3, 2025↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 4,361 | $1.73 | $7.5K | 0 |
| Feb 3, 2025↗ | Roberts Zachary | EVP of R&D | Sell | 18,832 | $1.70 | $32.0K | 0 |
| Jan 21, 2025↗ | Roberts Zachary | EVP of R&D | Sell | 27,199 | $1.78 | $48.4K | 0 |
| Dec 9, 2024↗ | MESSEMER DEBORAH M. | Director | Sell | 9,136 | $2.18 | $19.9K | 0 |
| Dec 5, 2024↗ | Humer Franz B | Director | Sell | 9,221 | $2.16 | $19.9K | 0 |
| Oct 21, 2024↗ | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,404 | $2.84 | $103.4K | 0 |
| Aug 21, 2024↗ | Douglas Earl Martin | SVP, General Counsel | Sell | 28,310 | $2.79 | $78.8K | 0 |
| Jun 18, 2024↗ | MESSEMER DEBORAH M. | Director | Sell | 18,641 | $2.28 | $42.5K | 0 |
| May 30, 2024↗ | Humer Franz B | Director | Sell | 11,200 | $2.34 | $26.2K | 0 |
| Apr 22, 2024↗ | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 17,360 | $3.47 | $60.2K | 0 |
| Mar 14, 2024↗ | Chang David D | President and CEO | Sell | 53,393 | $4.33 | $231.2K | 0 |
| Jan 22, 2024↗ | Roberts Zachary | EVP of R&D | Sell | 24,690 | $3.17 | $78.4K | 0 |
| Dec 18, 2023↗ | MESSEMER DEBORAH M. | Director | Sell | 18,640 | $2.70 | $50.3K | 0 |
| Aug 7, 2023↗ | Mayo Stephen | Director | Sell | 10,000 | $4.29 | $42.9K | 0 |
| Mar 14, 2023↗ | Bhavnagri Veer | General Counsel | Sell | 23,628 | $5.67 | $134.0K | 0 |
| Mar 14, 2023↗ | Chang David D | President and CEO | Sell | 22,340 | $5.56 | $124.2K | 0 |
| Mar 14, 2023↗ | MOORE ALISON | Chief Technical Officer | Sell | 8,351 | $5.51 | $46.0K | 0 |
| Mar 14, 2023↗ | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 35,879 | $5.47 | $196.3K | 0 |
| Feb 13, 2023↗ | Bhavnagri Veer | General Counsel | Sell | 3,000 | $6.85 | $20.6K | 0 |
| Jan 17, 2023↗ | Bhavnagri Veer | General Counsel | Sell | 3,000 | $7.04 | $21.1K | 0 |
| Dec 15, 2022↗ | Bhavnagri Veer | General Counsel | Sell | 5,602 | $7.53 | $42.2K | 0 |
| Oct 7, 2022↗ | Amado Rafael | EVP of R&D | Sell | 8,464 | $11.83 | $100.1K | 0 |
| Oct 3, 2022↗ | Amado Rafael | EVP of R&D | Sell | 8,968 | $11.06 | $99.2K | 0 |
| Aug 11, 2022↗ | WITTE OWEN N. | Director | Sell | 30,000 | $16.75 | $502.5K | 0 |
| Aug 2, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.97 | $23.9K | 0 |
| Jul 5, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.44 | $22.9K | 0 |
| Jun 22, 2022↗ | WITTE OWEN N. | Director | Sell | 10,000 | $11.76 | $117.6K | 0 |
| Jun 21, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.18 | $22.4K | 0 |
| May 19, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 11,500 | $7.40 | $85.1K | 0 |
| Mar 15, 2022↗ | Amado Rafael | EVP of R&D and CMO | Sell | 5,169 | $7.71 | $39.8K | 0 |
| Mar 15, 2022↗ | Bhavnagri Veer | General Counsel | Sell | 8,849 | $7.68 | $68.0K | 0 |
| Mar 15, 2022↗ | Chang David D | President and CEO | Sell | 23,648 | $7.65 | $180.9K | 0 |
| Mar 15, 2022↗ | MOORE ALISON | Chief Technical Officer | Sell | 8,698 | $7.63 | $66.4K | 0 |
| Mar 15, 2022↗ | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 11,469 | $7.63 | $87.6K | 0 |
| Oct 1, 2021↗ | Amado Rafael | EVP of R&D and CMO | Sell | 11,507 | $24.35 | $280.2K | 0 |
| Sep 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $24.77 | $123.8K | 0 |
| Sep 9, 2021↗ | WITTE OWEN N. | Director | Sell | 5,000 | $25.54 | $127.7K | 0 |
| Aug 20, 2021↗ | WITTE OWEN N. | Director | Sell | 10,000 | $23.47 | $234.7K | 0 |
| Aug 16, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $21.00 | $105.0K | 0 |
| Jul 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $21.55 | $107.8K | 0 |
| Jun 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $25.32 | $126.6K | 0 |
| Jun 9, 2021↗ | WITTE OWEN N. | Director | Sell | 9,969 | $25.05 | $249.7K | 0 |
| May 18, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $30.00 | $150.0K | 0 |
| May 17, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 5,000 | $28.30 | $141.5K | 0 |
| Apr 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 10,000 | $32.05 | $320.5K | 0 |
| Mar 15, 2021↗ | Amado Rafael | EVP of R&D and CMO | Sell | 2,798 | $38.05 | $106.5K | 0 |
| Mar 15, 2021↗ | Bhavnagri Veer | General Counsel | Sell | 16,623 | $37.95 | $630.8K | 0 |
| Mar 15, 2021↗ | Chang David D | President and CEO | Sell | 20,513 | $38.57 | $791.3K | 0 |
| Mar 15, 2021↗ | MOORE ALISON | Chief Technical Officer | Sell | 6,164 | $38.14 | $235.1K | 0 |
| Mar 15, 2021↗ | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 8,053 | $38.23 | $307.9K | 0 |
ALLO Insiders
Similar Stocks to ALLO
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B